Geneva Capital Management LLC Raises Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Geneva Capital Management LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 865,266 shares of the medical equipment provider’s stock after acquiring an additional 965 shares during the quarter. Geneva Capital Management LLC’s holdings in BioLife Solutions were worth $21,666,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. 1620 Investment Advisors Inc. purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $35,000. GAMMA Investing LLC grew its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions in the 2nd quarter valued at $122,000. Summit Global Investments purchased a new stake in shares of BioLife Solutions during the 3rd quarter worth $228,000. Finally, Arizona State Retirement System purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $217,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the sale, the executive vice president now owns 317,716 shares in the company, valued at $7,396,428.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,396,428.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,044 shares of company stock worth $645,105. 2.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BLFS. Craig Hallum lifted their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. TD Cowen lifted their price target on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Northland Securities upped their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, HC Wainwright started coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They set a “buy” rating and a $29.00 target price for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $26.67.

BioLife Solutions Price Performance

BLFS opened at $26.50 on Wednesday. The business has a 50 day simple moving average of $24.13 and a 200-day simple moving average of $22.72. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. BioLife Solutions, Inc. has a 12 month low of $9.92 and a 12 month high of $27.54.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.